An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Hepatic Impairment and in Matched Healthy Volunteers

Trial Profile

An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Hepatic Impairment and in Matched Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2016

At a glance

  • Drugs Emricasan (Primary)
  • Indications Alcoholic hepatitis; Hepatic fibrosis; Liver failure; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Conatus Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Apr 2015 According to a Conatus Pharmaceuticals media release, results will be presented at The International Liver Congress™ 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL).
    • 11 Mar 2015 According to a Conatus Pharmaceuticals media release, aggregate top-line results from this and two other (phase I and phase IIb) trials (n=73) in five distinct organ impairment patient populations were released in Jan 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top